GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 1 filers reported holding GRITSTONE ONCOLOGY INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $59,902 | +406.4% | 34,827 | +474.1% | 0.00% | – |
Q2 2023 | $11,829 | +65616.7% | 6,066 | -9.3% | 0.00% | -100.0% |
Q1 2023 | $18 | -14.3% | 6,689 | +11.7% | 0.00% | 0.0% |
Q4 2022 | $21 | -99.9% | 5,990 | -51.4% | 0.00% | 0.0% |
Q3 2022 | $31,000 | +138.5% | 12,325 | +134.0% | 0.00% | – |
Q2 2022 | $13,000 | -86.7% | 5,266 | -77.9% | 0.00% | -100.0% |
Q1 2022 | $98,000 | +71.9% | 23,855 | +438.7% | 0.00% | 0.0% |
Q4 2021 | $57,000 | -66.1% | 4,428 | -71.5% | 0.00% | -75.0% |
Q3 2021 | $168,000 | +158.5% | 15,524 | +116.9% | 0.00% | +100.0% |
Q2 2021 | $65,000 | -30.1% | 7,157 | -26.9% | 0.00% | 0.0% |
Q1 2021 | $93,000 | +244.4% | 9,787 | +43.9% | 0.00% | +100.0% |
Q4 2020 | $27,000 | -69.0% | 6,800 | -79.3% | 0.00% | 0.0% |
Q3 2020 | $87,000 | +93.3% | 32,841 | +385.6% | 0.00% | -50.0% |
Q2 2020 | $45,000 | +542.9% | 6,763 | +739.1% | 0.00% | – |
Q3 2019 | $7,000 | 0.0% | 806 | +56.5% | 0.00% | – |
Q1 2019 | $7,000 | +600.0% | 515 | +560.3% | 0.00% | – |
Q4 2018 | $1,000 | – | 78 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |